Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Leora Horn

Medical Oncology Nashville, TN Medical Doctor

NPI 1487881041 CMS profile 67611

3601 Tvc, Nashville, TN 37232

Open in the dashboard

General payments

$97,754

64 records reported · program years 2019–2021

Research payments

$7,948

Paid to them · 9 records reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,501,467 paid to institutions, not to them · program years 2019–2024

Through program year 2021, Leora Horn of Nashville, TN is reported in the CMS Open Payments database as having received $97,754 across 64 general payments and $7,948 in research payments paid to them. Separately, studies naming them as principal investigator received $2,501,467 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $2,740 1
2021 Research $773 1
2020 General $34,435 13
2020 Research $7,175 8
2019 General $60,580 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leora Horn
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Leora Horn were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Leora Horn Medical Oncology median Middle half National median
2019 $60,580 $968 $140–$6,658 $163
2020 $34,435 $747 $102–$5,891 $114
2021 $2,740 $430 $50–$4,098 $132
2022 $0 $812 $127–$4,907 $149
2023 $0 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AstraZeneca Pharmaceuticals LP $24,384 17 payments
  2. Merck Sharp & Dohme Corporation $18,679 10 payments
  3. Pfizer Inc. $10,577 7 payments
  4. EMD Serono, Inc. $8,625 2 payments
  5. F. Hoffmann-La Roche AG $8,523 8 payments
  6. Hoffmann-La Roche Limited $7,693 2 payments
  7. Incyte Corporation $4,989 5 payments
  8. Genentech USA, Inc. $4,856 4 payments
  9. AstraZeneca UK Limited $3,350 2 payments
  10. Amgen Inc. $3,300 2 payments
  11. Other $2,778 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Consulting Fee $80,305 20 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,463 7 payments
  3. Travel and Lodging $4,583 13 payments
  4. Food and Beverage $4,403 24 payments
Products named General payments · program years 2019–2021
  1. TECENTRIQ $16,619 12 payments
  2. TAGRISSO $13,280 4 payments
  3. IMFINZI Cardiovascular And Metabolism $6,543 3 payments
  4. Alecensa $4,856 4 payments
  5. ROZLYTREK $4,856 4 payments
  6. BAVENCIO $4,000 1 payment
  7. IMFINZI Oncology $2,740 1 payment
  8. Tepotinib $2,625 1 payment
  9. IMFINZI Oncology $528 7 payments
  10. KEYTRUDA $136 3 payments
  11. Other $84 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2021
  1. F. Hoffmann-La Roche AG $7,948 9 payments

Records

73 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record